Novartis AG (NVS) Ramps Up Alzheimer's Drug Pursuit as Rivals Fail
5/22/2013 7:46:32 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Novartis AG (NOVN) plans to ramp up its research in Alzheimer’s disease, a potential $20 billion market lacking a major contender and littered with three high-profile drug failures in the past year alone. “This remains high on our radar, with high unmet medical need,” Tim Wright, who heads the Basel, Switzerland-based company’s drug development, said on a conference call arranged by Sanford C. Bernstein & Co. analyst Tim Anderson in April. Novartis didn’t respond to a request for comment on its Alzheimer’s research. Novartis would be racing to catch up with Roche Holding AG (ROG) and Merck & Co. (MRK), which are conducting human tests on treatments for Alzheimer’s, the most common dementia illness. Drugmakers are vying to find a way to slow the disease, which may affect 65 million people by 2030. The field is marked with failures, including a study Baxter International Inc. (BAX) released this month in which its Gammagard drug didn’t help patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by